Selective androgen receptor degrader (SARD) ligands and methods of use thereof

A method of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting the progression of Kennedy's disease in a subject, comprising administering to said subject a therapeutically effective amount of compound 17

• or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof.

A method of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting the progression of amyotrophic lateral sclerosis (ALS) in a subject, comprising administering to said subject a therapeutically effective amount of compound

• or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof.

A method of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting the progression of AR-positive cancer that is resistant to treatment with an androgen receptor antagonist and/or a lyase inhibitor, comprising administering to said subject a therapeutically effective amount of compound 17

• or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof.

A method of treating abdominal aortic aneurysm (AAA) in a subject, comprising administering to said subject a therapeutically effective amount of compound

• or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof.

A method of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting the progression of a hyperandrogenic hormonal condition in a female, comprising administering to said subject a therapeutically effective amount of compound

• or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof,
• wherein said hyperandrogenic hormonal condition in a female is precocious puberty, early puberty, dysmenorrhea, amenorrhea, multilocular uterus syndrome, endometriosis, hysteromyoma, abnormal uterine bleeding, early menarche, fibrocystic breast disease, fibroids of the uterus, ovarian cysts, polycystic ovary syndrome, pre-eclampsia, eclampsia of pregnancy, preterm labor, premenstrual syndrome, and/or vaginal dryness.

A topical pharmaceutical composition comprising compound 17

• or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof, and a pharmaceutically acceptable carrier.